Linaclotide Formulation Stability via Polymer and Amine Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved formulations of linaclotide with enhanced stability and performance properties to effectively treat gastrointestinal disorders such as irritable bowel syndrome and constipation.
Innovation Solution
The development of stable pharmaceutical compositions comprising linaclotide with a polymer, a sterically hindered primary amine, and a cation, which together enhance the stability of linaclotide by preventing degradation reactions and forming a stable matrix, thereby improving its therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If linaclotide is formulated without stabilizing agents, then the formulation is simpler, but the stability and bioavailability of linaclotide deteriorate
Solution Approach 1:
The patent introduces polymers (such as polyvinyl pyrrolidone), sterically hindered primary amines (such as leucine), and cations (such as calcium ions) as intermediary substances that mediate between linaclotide and the formulation environment. These stabilizing agents form a protective matrix around linaclotide, preventing degradation reactions and improving stability without significantly complicating the formulation process
Solution Approach 2:
The patent creates a composite formulation system where linaclotide is combined with multiple stabilizing agents (polymers, amines, and cations) that work synergistically. This composite approach forms a stable matrix that protects linaclotide from degradation while maintaining simplicity in formulation methodology
2Stability of the object's composition
If stabilizing agents are added to improve linaclotide stability, then the stability increases, but the formulation complexity increases
Solution Approach 1:
The patent optimizes the concentrations and ratios of stabilizing agents (polymers, sterically hindered primary amines, and cations) to achieve maximum stability with minimal formulation complexity. By carefully controlling these parameters, the formulation achieves enhanced linaclotide stability without requiring complex multi-component systems
3Reliability
If degradation reactions are prevented through stabilizing agents, then the bioavailability improves, but the manufacturing process becomes more complex
Solution Approach 1:
The patent incorporates stabilizing agents (polymers, sterically hindered primary amines, and cations) into the formulation during the manufacturing process to preemptively prevent degradation reactions. This preliminary protection ensures high bioavailability of linaclotide while maintaining straightforward manufacturing procedures, as the stabilizing agents are integrated into the base formulation without requiring additional complex processing steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inclusion of polymers like polyvinyl pyrrolidone, sterically hindered amines like leucine, and cations like calcium ions in the composition significantly increases the stability and bioavailability of linaclotide, leading to effective treatment of gastrointestinal disorders with improved stability and performance.
Implementation Method 1
which together enhance the stability of linaclotide by preventing degradation reactions and forming a stable matrix
Implementation Method 2
The inclusion of polymers like polyvinyl pyrrolidone, sterically hindered amines like leucine, and cations like calcium ions in the composition significantly increases the stability and bioavailability of linaclotide
Data Source
AI summary
The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.